163 related articles for article (PubMed ID: 20369276)
1. Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.
An G; Morris ME
Pharm Res; 2010 Jul; 27(7):1296-308. PubMed ID: 20369276
[TBL] [Abstract][Full Text] [Related]
2. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Mol Pharmacol; 2004 May; 65(5):1208-16. PubMed ID: 15102949
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Pharm Res; 2004 Jul; 21(7):1263-73. PubMed ID: 15290869
[TBL] [Abstract][Full Text] [Related]
4. Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo.
An G; Morris ME
Biopharm Drug Dispos; 2010 Jul; 31(5-6):340-50. PubMed ID: 20535833
[TBL] [Abstract][Full Text] [Related]
5. 5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice.
An G; Wu F; Morris ME
Pharm Res; 2011 May; 28(5):1090-9. PubMed ID: 21279423
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of inhibitory effects of flavonoids on breast cancer resistance protein (BCRP): From library screening to biological evaluation to structure-activity relationship.
Fan X; Bai J; Zhao S; Hu M; Sun Y; Wang B; Ji M; Jin J; Wang X; Hu J; Li Y
Toxicol In Vitro; 2019 Dec; 61():104642. PubMed ID: 31493543
[TBL] [Abstract][Full Text] [Related]
7. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
8. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
9. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.
Zhang S; Yang X; Coburn RA; Morris ME
Biochem Pharmacol; 2005 Aug; 70(4):627-39. PubMed ID: 15979586
[TBL] [Abstract][Full Text] [Related]
10. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
11. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
12. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A.
Woehlecke H; Osada H; Herrmann A; Lage H
Int J Cancer; 2003 Dec; 107(5):721-8. PubMed ID: 14566821
[TBL] [Abstract][Full Text] [Related]
13. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.
Wang X; Morris ME
Drug Metab Dispos; 2007 Feb; 35(2):268-74. PubMed ID: 17093006
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
Elahian F; Kalalinia F; Behravan J
Drug Chem Toxicol; 2010 Apr; 33(2):113-9. PubMed ID: 20307139
[TBL] [Abstract][Full Text] [Related]
17. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
Minderman H; O'Loughlin KL; Pendyala L; Baer MR
Clin Cancer Res; 2004 Mar; 10(5):1826-34. PubMed ID: 15014037
[TBL] [Abstract][Full Text] [Related]
18. Glucosamine attenuates drug resistance in Mitoxantrone-resistance breast cancer cells.
Valinezhad Sani F; Palizban A; Mosaffa F; Jamialahmadi K
J Pharm Pharmacol; 2021 Jun; 73(7):922-927. PubMed ID: 33885909
[TBL] [Abstract][Full Text] [Related]
19. A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2).
Mahringer A; Delzer J; Fricker G
Eur J Pharm Biopharm; 2009 Aug; 72(3):605-13. PubMed ID: 19572416
[TBL] [Abstract][Full Text] [Related]
20. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
